Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 14 recruiting now early-phase tilt

Healthy Subjects: early-phase trial registry

14 of 70 indexed Healthy Subjects trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #198 of 28,707 conditions by registered trial count.

70 US clinical trials · 14 currently recruiting · #198 of 28,707 conditions by registered trial count

Healthy Subjects: 70 US clinical trials tracked, 14 recruiting.

Healthy Subjects is the subject of 70 registered US clinical trials on ClinicalTrials.gov, 14 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 50 in Phase 1-2 (earlier-stage). The most active sponsor is GlaxoSmithKline, running 7 of these trials.

Enrollment posture brief

Registry condition healthy-subjects

OPEN 14 | RECR 20% | LATE 1 | EARLY 50 | RANK #198 | SPON 7

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)

Metastatic Castration-Resist64.3%Brain Tumor47.9%Kidney Cancer27.5%Atherosclerosis22.9%Healthy Subjects (this)20%
Open-enrollment share among volume-matched conditions near Healthy Subjects

Healthy Subjects lists 14 open slots (20% of 70 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Healthy Subjects on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Healthy Subjects is recruiting below its size-band peers.

    14 of 70 indexed trials (20%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Healthy Subjects trials is spread across many organizations.

    GlaxoSmithKline accounts for 7 of 70 trials (10%). 48 distinct sponsors appear on at least one study for this condition label.

  3. Most Healthy Subjects trials plan to enrol fewer than 100 people.

    Median target enrolment is 32 among the 70 trials that report a genuine target (sentinel values excluded). 58 of those (82.9%) plan for fewer than 100 participants.

  4. Healthy Subjects research is mostly interventional.

    65 interventional and 5 observational studies make up this index (92.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 147Phase 23Phase 31

Open and recent trials

70 total, page 2 of 2

COMPLETED Phase 1 24 participants

A Single Oral Dose Study to Compare the Bioavailability Between Two Different Tablet Formulations and Assess if There is a Food Effect With the New Formulation

Astellas Pharma

NCT01484964

COMPLETED Phase 1 24 participants

A Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult Subjects

Astellas Pharma Global Development

NCT02111317

COMPLETED Phase 1 24 participants

A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Repaglinide and Caffeine

Astellas Pharma Global Development

NCT02128321

COMPLETED Phase 1 24 participants

A Study to Evaluate the Effect of Multiple Doses of Esomeprazole on the Pharmacokinetics of Isavuconazole

Astellas Pharma Global Development

NCT02128893

COMPLETED Phase 1 24 participants

Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789

Wyeth is now a wholly owned subsidiary of Pfizer

NCT00795730

COMPLETED Phase 2 23 participants

Effect of a Commercial Cosmetic Mouth Rinse on Plaque Re-growth

GlaxoSmithKline

NCT01122862

COMPLETED 22 participants

Effects of Systemically Administered Hydrocortisone on the Immune System in Healthy Volunteers

National Heart, Lung, and Blood Institute (NHLBI)

NCT01281995

COMPLETED Phase 1 21 participants

A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast

Amgen

NCT01561963

COMPLETED Phase 1 20 participants

GSK1349572 First Time in Human Study

GlaxoSmithKline

NCT00555035

COMPLETED Phase 1 18 participants

Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy Subjects

CTI BioPharma

NCT02807116

COMPLETED Phase 1 18 participants

Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets

ViiV Healthcare

NCT01366547

COMPLETED Phase 1 16 participants

Effect of Oral Adenosine-triphosphate (ATP) on Human Muscle Performance

Metabolic Technologies

NCT01141504

COMPLETED Phase 1 16 participants

Evaluate Retention of an Orally Administered Device Using Gamma Scintigraphy

Procter and Gamble

NCT00754091

COMPLETED Phase 1 12 participants

A Study to Examine the Absorption of GSK561679 in Healthy Male Volunteers

GlaxoSmithKline

NCT00539136

COMPLETED Phase 1 12 participants

DDI Study of Etravirine and GSK1265744

GlaxoSmithKline

NCT00920296

COMPLETED Phase 1 12 participants

A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961

Pfizer

NCT03492697

COMPLETED Phase 1 8 participants

Study to Evaluate the Pharmacokinetics of 14C-labeled Isavuconazole Following a Single Oral Dose of 14C-labeled Prodrug Isavuconazonium Sulfate (BAL8557) in Healthy Male Subjects

Astellas Pharma Global Development

NCT01813461

COMPLETED Phase 1 7 participants

An Open-Label, Single-Dose Study to Determine the Metabolism and Elimination of 14C-Perampanel in Healthy Male Subjects

Eisai

NCT02116907

COMPLETED Phase 1 6 participants

Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnaltrexone Versus Intravenous Dose

Bausch Health Americas

NCT01367496

COMPLETED Phase 1 6 participants

(+)-Alpha-Dihydrotetrabenazine Phase I

Kirk A. Frey

NCT02844179

← Previous Page 2 of 2

Phase Distribution

PhaseTrial count
Phase 1 47
Phase 2 3
Phase 3 1

Named interventions

Most-linked intervention names on Healthy Subjects records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
6 trials
Marketed paracetamol Drug
3 trials
Experimental paracetamol formulation Drug
3 trials
ASP015K Drug
2 trials
Isavuconazole Drug
2 trials
HTBZ Drug
1 trials
PF-06882961 Immediate Release Solution Drug
1 trials
PF-06882961 Controlled Release Tablet (short) Drug
1 trials

US sites by state

Facility locations filed on Healthy Subjects trials. A trial with sites in several states counts in each.

Maryland 11 trials
Texas 9 trials
California 9 trials
New York 6 trials
Nebraska 6 trials
Virginia 5 trials
Ohio 5 trials
Florida 5 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Healthy Subjects page

70 registered trials, 14 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 14 Healthy Subjects trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • GlaxoSmithKline sponsors the most Healthy Subjects trials on record, review their full trial history before evaluating a specific study. See GlaxoSmithKline's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Healthy Subjects condition card totals 70 registered trials; most-linked intervention Placebo; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.